Which has better earnings and valuation, 4BB or AVCT?

4basebio has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 4basebio £1.69M 47.54 -£9.84M -£109.00 N/A Avacta Group £113K 2,768.58 -£30.08M -£9.66 N/A

Is 4BB or AVCT more profitable?

4basebio has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. 4basebio's return on equity of -231.29% beat Avacta Group's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% Avacta Group -33,961.06% -2,929.47% -21.80%

Do analysts prefer 4BB or HZD?

4basebio presently has a consensus price target of GBX 1,400, suggesting a potential upside of 169.36%. Given 4basebio's stronger consensus rating and higher probable upside, research analysts clearly believe 4basebio is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is 4BB or HZD more profitable?

Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% Horizon Discovery Group plc (HZD.L) N/A N/A N/A

Is 4BB or PRTC more profitable?

4basebio has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% PureTech Health -2,355.32% -31.98% -13.39%

Do analysts prefer 4BB or ARIX?

4basebio presently has a consensus price target of GBX 1,400, indicating a potential upside of 169.36%. Given 4basebio's stronger consensus rating and higher probable upside, equities research analysts clearly believe 4basebio is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, 4BB or ARIX?

Arix Bioscience has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 4basebio £1.69M 47.54 -£9.84M -£109.00 N/A Arix Bioscience £14.16M 0.00 £14.96M £0.11 N/A

Do analysts rate CIR or 4BB?

4basebio has a consensus target price of GBX 1,400, suggesting a potential upside of 169.36%. Given 4basebio's stronger consensus rating and higher possible upside, analysts plainly believe 4basebio is more favorable than Circassia Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Circassia Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is CIR or 4BB more profitable?

Circassia Group's return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets Circassia Group N/A N/A N/A 4basebio N/A -231.29% -54.30%

4basebio (4BB) Competitors

GBX 519.75 0.00 (0.00%)

As of 05:31 AM Eastern

Compare

4BB vs. AVCT, HZD, PRTC, ARIX, and CIR

Should you buy 4basebio stock or one of its competitors? MarketBeat compares 4basebio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 4basebio include Avacta Group (AVCT), Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), Arix Bioscience (ARIX), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry.

How does 4basebio compare to Avacta Group?

4basebio (LON:4BB) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

4basebio has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. 4basebio's return on equity of -231.29% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

0.9% of 4basebio shares are held by institutional investors. Comparatively, 3.1% of Avacta Group shares are held by institutional investors. 12.1% of 4basebio shares are held by insiders. Comparatively, 47.7% of Avacta Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

4basebio presently has a consensus price target of GBX 1,400, indicating a potential upside of 169.36%. Avacta Group has a consensus price target of GBX 99, indicating a potential upside of 48.27%. Given 4basebio's higher probable upside, research analysts plainly believe 4basebio is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

4basebio has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

4basebio has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	47.54	-£9.84M	-£109.00	N/A
Avacta Group	£113K	2,768.58	-£30.08M	-£9.66	N/A

In the previous week, Avacta Group had 1 more articles in the media than 4basebio. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for 4basebio. Avacta Group's average media sentiment score of 0.67 beat 4basebio's score of 0.00 indicating that Avacta Group is being referred to more favorably in the news media.

Company	Overall Sentiment
4basebio	Neutral
Avacta Group	Positive

Summary

Avacta Group beats 4basebio on 8 of the 14 factors compared between the two stocks.

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

4basebio (LON:4BB) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	47.54	-£9.84M	-£109.00	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

4basebio presently has a consensus price target of GBX 1,400, suggesting a potential upside of 169.36%. Given 4basebio's stronger consensus rating and higher probable upside, research analysts clearly believe 4basebio is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

0.9% of 4basebio shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, 4basebio's average media sentiment score of 0.00 equaled Horizon Discovery Group plc (HZD.L)'saverage media sentiment score.

Company	Overall Sentiment
4basebio	Neutral
Horizon Discovery Group plc (HZD.L)	Neutral

Summary

4basebio beats Horizon Discovery Group plc (HZD.L) on 6 of the 10 factors compared between the two stocks.

How does 4basebio compare to PureTech Health?

4basebio (LON:4BB) and PureTech Health (LON:PRTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

4basebio has higher earnings, but lower revenue than PureTech Health. 4basebio is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	47.54	-£9.84M	-£109.00	N/A
PureTech Health	£4.66M	62.49	-£91.86M	-£46.00	N/A

4basebio has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.771, meaning that its stock price is 23% less volatile than the broader market.

In the previous week, 4basebio's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Overall Sentiment
4basebio	Neutral
PureTech Health	Neutral

4basebio currently has a consensus target price of GBX 1,400, suggesting a potential upside of 169.36%. PureTech Health has a consensus target price of GBX 508, suggesting a potential upside of 324.75%. Given PureTech Health's higher possible upside, analysts plainly believe PureTech Health is more favorable than 4basebio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

0.9% of 4basebio shares are held by institutional investors. Comparatively, 32.5% of PureTech Health shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Comparatively, 13.4% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

4basebio has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Summary

PureTech Health beats 4basebio on 9 of the 12 factors compared between the two stocks.

How does 4basebio compare to Arix Bioscience?

4basebio (LON:4BB) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

4basebio has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

4basebio presently has a consensus price target of GBX 1,400, indicating a potential upside of 169.36%. Given 4basebio's stronger consensus rating and higher probable upside, equities research analysts clearly believe 4basebio is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, 4basebio's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company	Overall Sentiment
4basebio	Neutral
Arix Bioscience	Neutral

Arix Bioscience has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	47.54	-£9.84M	-£109.00	N/A
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

Arix Bioscience has a net margin of 105.64% compared to 4basebio's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
Arix Bioscience	105.64%	6.41%	2.18%

0.9% of 4basebio shares are owned by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are owned by institutional investors. 12.1% of 4basebio shares are owned by company insiders. Comparatively, 20.7% of Arix Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Arix Bioscience beats 4basebio on 9 of the 13 factors compared between the two stocks.

How does 4basebio compare to Circassia Group?

Circassia Group (LON:CIR) and 4basebio (LON:4BB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

0.9% of 4basebio shares are owned by institutional investors. 12.1% of 4basebio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Circassia Group has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A
4basebio	£1.69M	47.54	-£9.84M	-£109.00	N/A

4basebio has a consensus target price of GBX 1,400, suggesting a potential upside of 169.36%. Given 4basebio's stronger consensus rating and higher possible upside, analysts plainly believe 4basebio is more favorable than Circassia Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Circassia Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Circassia Group's return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Circassia Group	N/A	N/A	N/A
4basebio	N/A	-231.29%	-54.30%

In the previous week, Circassia Group's average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company	Overall Sentiment
Circassia Group	Neutral
4basebio	Neutral

Summary

Circassia Group and 4basebio tied by winning 5 of the 10 factors compared between the two stocks.

Get 4basebio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding 4BB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

4BB vs. The Competition

Export

Metric	4basebio	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£80.48M	£3.69B	£7.00B	£2.88B
Dividend Yield	N/A	3.76%	2.58%	6.11%
P/E Ratio	-4.77	9.02	270.57	368.39
Price / Sales	47.54	1,291.29	659.56	83,667.21
Price / Cash	16.08	44.95	28.89	27.89
Price / Book	-12.68	17.52	11.20	7.19
Net Income	-£9.84M	-£13.25M	£3.45B	£5.89B
7 Day Performance	-5.50%	5.02%	3.39%	1.61%
1 Month Performance	-5.50%	-2.12%	-0.72%	2.40%
1 Year Performance	-44.88%	61.49%	77.42%	74.99%

4basebio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
4BB 4basebio	N/A	GBX 519.75 flat	GBX 1,400 +169.4%	-44.9%	£80.48M	£1.69M	N/A	101
AVCT Avacta Group	2.684 of 5 stars	GBX 66.61 -1.9%	GBX 99 +48.6%	+46.9%	£318.14M	£113K	N/A	120
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	2.3463 of 5 stars	GBX 119.12 -0.4%	GBX 508 +326.5%	-11.9%	£291.13M	£4.66M	N/A	300	Positive News
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:4BB) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4basebio (4BB) Competitors

4BB vs. AVCT, HZD, PRTC, ARIX, and CIR

How does 4basebio compare to Avacta Group?

Summary

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does 4basebio compare to PureTech Health?

Summary

How does 4basebio compare to Arix Bioscience?

Summary

How does 4basebio compare to Circassia Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

4BB vs. The Competition

4basebio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4basebio (4BB) Competitors

4BB vs. AVCT, HZD, PRTC, ARIX, and CIR

How does 4basebio compare to Avacta Group?

Is 4BB or AVCT more profitable?

Do insiders and institutionals believe in 4BB or AVCT?

Do analysts rate 4BB or AVCT?

Which has more risk and volatility, 4BB or AVCT?

Which has better earnings and valuation, 4BB or AVCT?

Does the media prefer 4BB or AVCT?

Summary

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Which has higher earnings & valuation, 4BB or HZD?

Do analysts prefer 4BB or HZD?

Is 4BB or HZD more profitable?

Do institutionals and insiders have more ownership in 4BB or HZD?

Does the media refer more to 4BB or HZD?

Summary

How does 4basebio compare to PureTech Health?

Which has preferable valuation & earnings, 4BB or PRTC?

Which has more risk & volatility, 4BB or PRTC?

Does the media prefer 4BB or PRTC?

Do analysts prefer 4BB or PRTC?

Do insiders and institutionals have more ownership in 4BB or PRTC?

Is 4BB or PRTC more profitable?

Summary

How does 4basebio compare to Arix Bioscience?

Which has more volatility and risk, 4BB or ARIX?

Do analysts prefer 4BB or ARIX?

Does the media refer more to 4BB or ARIX?

Which has preferable valuation & earnings, 4BB or ARIX?

Is 4BB or ARIX more profitable?

Do insiders & institutionals have more ownership in 4BB or ARIX?

Summary

How does 4basebio compare to Circassia Group?

Do institutionals and insiders hold more shares of CIR or 4BB?

Which has preferable valuation & earnings, CIR or 4BB?

Do analysts rate CIR or 4BB?

Is CIR or 4BB more profitable?

Does the media refer more to CIR or 4BB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

4BB vs. The Competition

4basebio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools